AI assistant
HAEMONETICS CORP — Director's Dealing 2014
Feb 10, 2014
31565_dirs_2014-02-10_2dd01bdd-7f43-488d-959a-b91f8b5677bf.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2014-02-07
Reporting Person: White Jonathan (Chief Science and Technology)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2014-02-07 | Common Stock | S | 700.0 | $38.66 | Disposed | 26346 | Direct |
| 2014-02-07 | Common Stock | S | 315.0 | $38.672 | Disposed | 26031 | Direct |
| 2014-02-07 | Common Stock | S | 865.0 | $38.66 | Disposed | 25166 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy) | $26.47 | 2016-10-27 | Common Stock (24484) | 24484 | Direct |
| Non-Qualified Stock Option (right to buy) | $27.495 | 2017-10-27 | Common Stock (30776) | 30776 | Direct |
| Non-Qualified Stock Option (right to buy) | $30.025 | 2016-01-28 | Common Stock (35282) | 35282 | Direct |
| Non-Qualified Stock Option (right to buy) | $30.67 | 2018-10-25 | Common Stock (35130) | 35130 | Direct |
| Non-Qualified Stock Option (right to buy) | $33.925 | 2018-07-20 | Common Stock (27948) | 27948 | Direct |
| Non-Qualified Stock Option (right to buy) | $39.055 | 2019-10-24 | Common Stock (32192) | 32192 | Direct |
| Non-Qualified Stock Option (right to buy) | $41.66 | 2019-10-23 | Common Stock (28523) | 28523 | Direct |
| Performance Shares | $0.0 | 2017-12-31 | Common Stock (25000) | 25000 | Direct |
Footnotes
F1: Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant.
F2: Market Share Units represent a right to receive one share of Haemonetics Corporation common stock for each Market Stock Unit based on Haemonetics stock price during the 30 trading days prior to March 31, 2017. The number of Market Stock Units (and therefore the number of shares payable) will depend on the Companys stock price during such period. The Market Stock Units disclosed in column 5 represent a target amount. The number of shares ultimately issued could range from none to three times the target amount in column 5. The Market Stock Units were granted under the 2005 Haemonetics Corporation Long-Term Incentive Compensation Plan and are exempt under Rule 16b-3(d).